Investors

Financials & Filings

Filing date Form Description Filing Group View
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
4

Statement of changes in beneficial ownership of securities

3,4,5
SC 13D/A

An amendment to a SC 13D filing

Other
424B3

Form of prospectus reflecting facts events constituting substantive change from last form

Registration Statements
SC 13D/A

An amendment to a SC 13D filing

Other
S-8

Securities offered to employees pursuant to employee benefit plans

Registration Statements

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.